View Item 

Show simple item record

B‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity?
dc.contributor.authorKalra, Vaneet Kumaren_US
dc.contributor.authorAggarwal, Sanjeeven_US
dc.contributor.authorArora, Premen_US
dc.contributor.authorNatarajan, Girijaen_US
dc.date.accessioned2014-11-04T16:35:09Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-11-04T16:35:09Z
dc.date.issued2014-11en_US
dc.identifier.citationKalra, Vaneet Kumar; Aggarwal, Sanjeev; Arora, Prem; Natarajan, Girija (2014). "B‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity?." Pediatric Pulmonology 49(11): 1106-1111.en_US
dc.identifier.issn8755-6863en_US
dc.identifier.issn1099-0496en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109265
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherChronic Lung Diseaseen_US
dc.subject.otherPreterm Neonatesen_US
dc.subject.otherB‐Type Natriuretic Peptideen_US
dc.titleB‐type natriuretic peptide levels in preterm neonates with bronchopulmonary dysplasia: A marker of severity?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109265/1/ppul22942.pdf
dc.identifier.doi10.1002/ppul.22942en_US
dc.identifier.sourcePediatric Pulmonologyen_US
dc.identifier.citedreferenceCuna A, Kandasamy J, Fineberg N, Sims B. B‐type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol 2013; 3: 33 – 36.en_US
dc.identifier.citedreferenceVijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. B‐type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012; 160: 111 – 115, e111.en_US
dc.identifier.citedreferenceNuntnarumit P, Chongkongkiat P, Khositseth A. N‐terminal‐pro‐brain natriuretic peptide: a guide for early targeted indomethacin therapy for 1patent ductus arteriosus in preterm Infants. Acta Paediatr 100: 1217 – 1221.en_US
dc.identifier.citedreferenceJobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723 – 1729.en_US
dc.identifier.citedreferenceOlsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125: e214 – e224.en_US
dc.identifier.citedreferencePapile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92: 529 – 534.en_US
dc.identifier.citedreferenceWalsh M, Engle W, Laptook A, Kazzi SN, Buchter S, Rasmussen M, Yao Q. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved ? Pediatrics 2005; 116: 857 – 861.en_US
dc.identifier.citedreferenceBallard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343 – 353.en_US
dc.identifier.citedreferenceCantinotti M, Storti S, Parri MS, Murzi M, Clerico A. Reference values for plasma B‐type natriuretic peptide in the first days of life. Clin Chem 2009; 55: 1438 – 1440.en_US
dc.identifier.citedreferenceInoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009; 48: 503 – 512.en_US
dc.identifier.citedreferenceJoseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N‐terminal pro‐B‐type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27: 381 – 386.en_US
dc.identifier.citedreferenceAkcan AB, Kardelen F, Oygucu SE, Kocabaş A, Ozel D, Akbaş H, Oygür N. The efficacy of cardiac findings in assessing the outcome in preterms with bronchopulmonary dysplasia. Indian J Pediatr 2013. DOI 10.1007/s12098‐013‐0994‐yen_US
dc.identifier.citedreferenceMannarino S, Garofoli F, Mongini E, et al. BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants. Early Hum Dev 2010; 86: 295 – 298.en_US
dc.identifier.citedreferenceHill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994; 266: L308 – 315.en_US
dc.identifier.citedreferenceKlinger JR, Warburton RR, Pietras L, Hill NS. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol 1998; 84: 1646 – 1652.en_US
dc.identifier.citedreferenceNagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865 – 870.en_US
dc.identifier.citedreferenceCohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, Nir A. Amino‐terminal pro‐brain‐type natriuretic peptide: heart or lung disease in pediatric respiratory distress ? Pediatrics 2005; 115: 1347 – 1350.en_US
dc.identifier.citedreferenceParekh N, Maisel AS. Utility of B‐natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 2009; 24: 155 – 160.en_US
dc.identifier.citedreferenceCollaco JM, Romer LH, Stuart BD, et al. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol 2012; 47: 1042 – 1053.en_US
dc.identifier.citedreferenceNorthway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline‐membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357 – 368.en_US
dc.identifier.citedreferenceJobe AH. What is BPD in 2012 and what will BPD become ? Early Hum Dev 2012; 88: S27 – S28.en_US
dc.identifier.citedreferenceJobe AJ. The new BPD: an arrest of lung development. Pediatr Res Dec 1999; 46: 641 – 643.en_US
dc.identifier.citedreferenceMourani PM, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004; 170: 1006 – 1013.en_US
dc.identifier.citedreferenceKhemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120: 1260 – 1269.en_US
dc.identifier.citedreferenceYates AR, Welty SE, Gest AL, Cua CL. Myocardial tissue Doppler changes in patients with bronchopulmonary dysplasia. J Pediatr 2008; 152: 766 – 770, 770 e761.en_US
dc.identifier.citedreferenceMourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121: 317 – 325.en_US
dc.identifier.citedreferenceLevin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321 – 328.en_US
dc.identifier.citedreferenceGotze JP, Kastrup J. Plasma pro‐brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest Suppl 2001; 234: 47 – 51.en_US
dc.identifier.citedreferenceLaw YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B‐type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol 2009; 54: 1467 – 1475.en_US
dc.identifier.citedreferenceKalra VK, DeBari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F. Point‐of‐care testing for B‐type natriuretic peptide in premature neonates with patent ductus arteriosus. Ann Clin Lab Sci Spring 2011; 41: 131 – 137.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ppul22942.pdf
Size:
329.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.